Edgen AI operates independently of, and is not controlled by Aspen Digital Financial Limited.
Dyne Therapeutics wins FDA priority review for DMD drug, PDUFA Jan 2027
Edgen Stock·Jul 29 2026, 21:05Share to
Share to
Copy link
[1] Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights (https://www.globenewswire.com/news-release/20 ...)[2] Dyne Raises $431.4M in Public Offering as FDA Clears IND for FSHD siRNA Drug (https://www.precisionmedicineonline.com/busin ...)[3] Dyne raises $431M as FDA reviews Duchenne muscular dystrophy drug - Stock Titan (https://www.stocktitan.net/news/DYN/dyne-ther ...)[4] Dyne Therapeutics Net Loss Widens to $178.6 Million in Q2 2026 - Quiver Quantitative (https://www.quiverquant.com/news/Dyne+Therape ...)
Related News
Jul 29 2026, 21:58
Fed holds rates at 3.75% as dollar posts worst day in 4 weeks
**The Federal Reserve held interest rates steady at 3.75% on Wednesday, a decision that triggered the dollar's worst single-day decline in a month and pushed the yen to recover nearly 0.3% against the greenback.** The Federal Reserve held rates at 3.75% on Wednesday, but the dollar still posted its worst day in four weeks as markets interpreted the accompanying statement as dovish relative to hawkish expectations that had built into the decision. The vote was unanimous, with all 12 FOMC members backing the hold, according to the post-meeting statement. "The statement language was carefully calibrated to avoid signaling any near-term bias, but the market had priced in a roughly 30% chance of a hike, so the hold itself feels like a dovish surprise," said James Okafor, central bank analyst at Edgen. The dollar index slid 0.58% to 100.68, its steepest single-day drop in about four weeks. USD/JPY declined nearly 0.3% as the yen staged a late-session recovery, while GBP/USD rose 0.14% to 1.3365. The 2-year Treasury yield fell 8 basis points as traders pared rate-hike bets, with the 10-year yield declining to 4.12%. The decision resets the policy narrative heading into the Bank of England's rate announcement on Thursday and the Bank of Japan's meeting later this week. With the Fed on hold and the BOJ having lifted rates to 1% in June — a 31-year high — the rate differential that has driven dollar strength for much of the year is narrowing. ## Dollar Selloff Unwinds Pre-Fed Positioning The dollar's decline accelerated after the FOMC statement omitted language that would have kept a July hike on the table. Markets had assigned a 30% probability to a quarter-point increase, according to analyst estimates cited before the decision, after sticky inflation readings in the first half of the year kept the Fed on edge. The core PCE price index, the Fed's preferred inflation gauge, stood at 3.4% year-over-year in May, well above the central bank's 2% target. The last time the Fed held rates after a period of hawkish speculation was in September 2024, when the dollar subsequently weakened 1.2% over the following two weeks before rebounding. OIS markets now price a 62% probability of a hold at the September meeting, with the first full quarter-point cut not fully priced until the first quarter of 2027. The yen was the primary beneficiary of the dollar's retreat. USD/JPY fell nearly 0.3% during the session, extending a pullback from levels near the 165 handle that had prevailed earlier in the week. The move comes ahead of the BOJ's policy decision, where Governor Kazuo Ueda faces pressure to continue normalizing after June's rate increase to 1% — the highest since 1995. Japan's experience with premature tightening is instructive: in 2006-2007, Governor Toshihiko Fukui lifted rates only to 0.5% and ended quantitative easing, only for the BOJ to reverse course within two years. ## Cross-Asset Ripples and the Week Ahead The Fed's decision reverberated across asset classes. Gold held near $4,045 an ounce, grinding toward the $4,000 handle as a weaker dollar supported bullion. Crude oil saw a sharp divergence, with WTI jumping 6.39% to $82.10 on a larger-than-expected inventory draw of 7.167 million barrels, while Brent edged down 0.05% to $88.07. The Bank of England meets Thursday, with markets expecting a hold at 3.75% and a 7-2 vote split in favor of unchanged policy, according to economist surveys. UK data released Wednesday showed mortgage approvals rising to 58,200 in June from 56,570 in May, while M4 money supply expanded 0.8% month-over-month, both above consensus estimates. The Bank of Japan's decision later this week is shaping up as the most consequential of Ueda's tenure, with the choice between pausing further tightening for the rest of the year or accelerating the normalization cycle that began with June's rate increase. A stronger yen would signal confidence to investors and reduce Japan's reliance on imported inflation driven by elevated energy prices and an undervalued currency. If the BOJ holds firm, the dollar could face further pressure as the yield advantage that has supported the greenback for two years continues to erode. This article is for informational purposes only and does not constitute investment advice.
Jul 29 2026, 21:52
J&J joins in vivo CAR-T race as pharma bets $14B on technology
**Johnson & Johnson's collaboration with Sail Biomedicines marks the sixth major pharma bet on in vivo CAR-T therapy in two years, pushing total disclosed deal value past $14 billion as the industry races to solve cell therapy's access problem.** Johnson & Johnson (NYSE: JNJ) on Wednesday announced a strategic collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases, joining Eli Lilly, AbbVie and AstraZeneca in a technology arms race that has reshaped biotech dealmaking since early 2024. The partnership gives J&J access to Sail's platform for generating CAR-T cells inside the patient's body, eliminating the need to extract, engineer and reinfuse a patient's own cells. "The in vivo approach can fundamentally change how healthcare practitioners administer cell therapy," Mitchell Kapoor, senior biotech equity research analyst at H.C. Wainwright, said. "It could shorten time to infusion, cut the cost of cell therapy, and ultimately broaden access to hundreds of thousands of patients." Ex vivo CAR-T therapies, validated by Novartis' Kymriah in 2017 and followed by Bristol Myers Squibb's Breyanzi and Gilead's Yescarta, have proven effective against blood cancers but remain inaccessible to most eligible patients due to manufacturing complexity and cost. Kapoor said the ex vivo process "doesn't scale," constrained by the infrastructure required at treatment centers. In vivo CAR-T, by contrast, uses lipid nanoparticles or viral vectors to deliver genetic instructions directly into a patient's T cells, turning the body into its own manufacturing site. The deal underscores a broader industry shift. Lilly paid $2.4 billion in February to acquire Orna Therapeutics, gaining a circular RNA platform delivered via lipid nanoparticles for autoimmune indications, then followed with an up to $7 billion acquisition of Kelonia Therapeutics in April for KLN-1010, a lentiviral in vivo CAR-T candidate targeting BCMA in multiple myeloma. At ASCO 2026, KLN-1010 showed a 100% overall response rate across 18 patients, with all bone marrow samples testing negative for minimal residual disease at one month. AbbVie was an early mover, committing up to $1.4 billion in January 2024 to partner with Umoja Biopharma on its VivoVec lentiviral platform, then acquiring Capstan Therapeutics for up to $2.1 billion in June 2025 to add a lipid nanoparticle-based RNA approach. AstraZeneca entered the space in March 2025 with its up to $1 billion acquisition of EsoBiotec and the ENaBL platform, which generated Phase 1 data published in Nature Medicine showing that three of five multiple myeloma patients achieved complete cancer clearance. One patient died from grade 1 ICANS, a severe neurologic complication, highlighting the safety questions that shadow the field. **Safety remains the central question** Moving cell engineering from a controlled manufacturing facility into a patient's body introduces risks that ex vivo processes can mitigate through quality control at every step. "Once the vector's in, you're committed," Kapoor said. "Convenience and efficacy won't be enough to wow investors unless safety is pristine." Legend Biotech, which developed the approved ex vivo CAR-T therapy Carvykti with J&J, is also pursuing in vivo approaches. Its candidate LB2501, targeting CD19 and CD20, showed a 100% response rate in non-Hodgkin lymphoma patients in Phase 1 data disclosed last month, with no serious adverse events or dose-limiting toxicities. Oppenheimer analysts called the findings "best-in-class" and said they strengthen Legend's chances of becoming an acquisition target. Kostas Biliouris, managing director at Oppenheimer, described a "growing FOMO" among large pharma companies, noting that in vivo CAR-T could become the next major cell therapy platform if safety can be demonstrated at scale. The approach eliminates the need for preconditioning chemotherapy required in ex vivo protocols and could reduce the weeks-long manufacturing process to a single intravenous infusion. J&J did not disclose financial terms of the Sail collaboration. The companies said the partnership includes incentives to expand Sail's platform across additional therapeutic targets beyond the initial immune-mediated disease program. JNJ shares rose 1.2% in afternoon trading following the announcement. The stock trades at 16.2 times forward earnings, below the pharmaceutical peer average of 18.5 times, according to data compiled by Bloomberg. This article is for informational purposes only and does not constitute investment advice.
Jul 29 2026, 21:49
Canadian crude reaches Japan for first time in 18 months
A 750,000-barrel cargo of Canadian crude loaded via the Trans Mountain pipeline is headed to Japan, the first such shipment since early 2025, as the U.S.-Iran war disrupts Middle East supplies through the Strait of Hormuz. "Japan's renewed purchases of TMX crude highlight Canada's growing role in Asia's evolving import strategy as refiners diversify away from Middle East Gulf supplies," said Richard Ro, senior market analyst at Kpler. The Marshall Islands-flagged Aframax Freedom Glory, chartered by Exxon Mobil, was bought by Japan's largest refiner Eneos and is sailing to Kiire, Japan, according to Kpler and LSEG ship tracking data. Asian exports from Vancouver via the TMX pipeline have climbed to about 77% of total oil exports from the terminal in 2026, compared with roughly 51% in 2024. India, Malaysia and Singapore have all resumed purchases of TMX crude since the Iran war broke out at the end of February. The rerouting of global crude flows carries significant implications for pricing and supply security. With the Iran-aligned Houthis declaring a maritime embargo against Saudi Arabia and expanding attacks beyond the Gulf, Asian buyers face a prolonged period of supply uncertainty that is reshaping long-standing trade relationships and benefiting producers in the Americas. **TMX pipeline becomes Asia's alternative supply line** The Trans Mountain expansion, which began commercial operations in May 2024, has transformed Canada's ability to reach Pacific markets. Before TMX, Canadian producers were largely captive to U.S. Midwest refineries, selling at a discount to WTI. The pipeline now gives producers direct access to tidewater, where cargoes can command prices linked to global benchmarks rather than the inland AECO hub. Tourmaline Oil Corp., Canada's largest natural gas producer, reported Wednesday that it continues to benefit from its diversified marketing portfolio, with an average realized natural gas price of C$3.12 per mcf in the second quarter — C$1.46 above the AECO 5A benchmark. The company has an average of 1,014 mmcfpd hedged for the remainder of 2026 at a weighted average fixed price of C$4.97 per mcf, including 100 mmcfpd at a weighted average of C$16.25 in international markets. **What's at stake for global crude markets** The Iran conflict has removed a significant volume of crude from the global market. The Strait of Hormuz, through which about 20 million barrels per day of oil and refined products transit, has become a chokepoint that Asian buyers can no longer rely on exclusively. Japan, which imported roughly 3.3 million barrels per day of crude in 2025 — the vast majority from the Middle East — is now scrambling to diversify. For Canadian producers, the shift represents a structural opportunity. The TMX pipeline's capacity of 890,000 barrels per day gives Canada a meaningful — though still limited — share of the Asian crude market. If geopolitical tensions persist, further infrastructure investment in export capacity from Canada's west coast could accelerate, though regulatory and indigenous consultation timelines remain long. This article is for informational purposes only and does not constitute investment advice.